447 related articles for article (PubMed ID: 17442306)
41. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection.
Douradinha B; van Dijk MR; Ataide R; van Gemert GJ; Thompson J; Franetich JF; Mazier D; Luty AJ; Sauerwein R; Janse CJ; Waters AP; Mota MM
Int J Parasitol; 2007 Nov; 37(13):1511-9. PubMed ID: 17604034
[TBL] [Abstract][Full Text] [Related]
42. An alternative approach to malaria vaccine with a permanent attenuated mutant from a high virulence Plasmodium berghei strain.
Suzuki M; Waki S; Igarashi I; Takagi T; Miyagami T; Nakazawa S
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 May; 264(3-4):319-25. PubMed ID: 3310458
[TBL] [Abstract][Full Text] [Related]
43. Characterization of Pb51 in Plasmodium berghei as a malaria vaccine candidate targeting both asexual erythrocytic proliferation and transmission.
Wang J; Zheng W; Liu F; Wang Y; He Y; Zheng L; Fan Q; Luo E; Cao Y; Cui L
Malar J; 2017 Nov; 16(1):458. PubMed ID: 29132428
[TBL] [Abstract][Full Text] [Related]
44. Infection with Plasmodium berghei boosts antibody responses primed by a DNA vaccine encoding gametocyte antigen Pbs48/45.
Haddad D; Maciel J; Kumar N
Infect Immun; 2006 Apr; 74(4):2043-51. PubMed ID: 16552033
[TBL] [Abstract][Full Text] [Related]
45. [Protective immune mechanisms induced by cellular vaccine made of the erythrocytic Plasmodium yoelii].
Yuan J; Xu B; Liu BF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):47-51. PubMed ID: 15052774
[TBL] [Abstract][Full Text] [Related]
46. Monoclonal antibodies to a 140,000-m.w. protein on Plasmodium knowlesi merozoites inhibit their invasion of rhesus erythrocytes.
Miller LH; David PH; Hudson DE; Hadley TJ; Richards RL; Aikawa M
J Immunol; 1984 Jan; 132(1):438-42. PubMed ID: 6690607
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibodies. A tool in malaria research.
Epstein N
Dev Biol Stand; 1984; 57():129-32. PubMed ID: 6084604
[TBL] [Abstract][Full Text] [Related]
48. Effects of DNA vaccine in murine malaria using a full-length cDNA library.
Shibui A; Ohmori Y; Suzuki Y; Sasaki M; Nogami S; Sugano S; Watanabe J
Res Commun Mol Pathol Pharmacol; 2001; 109(3-4):147-57. PubMed ID: 11758646
[TBL] [Abstract][Full Text] [Related]
49. Recent progress in the development of malaria vaccines: memorandum from a WHO meeting.
Bull World Health Organ; 1984; 62(5):715-27. PubMed ID: 6391715
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
51. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate.
Zheng W; Liu F; He Y; Liu Q; Humphreys GB; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L
Parasit Vectors; 2017 Jan; 10(1):8. PubMed ID: 28057055
[TBL] [Abstract][Full Text] [Related]
52. Characterization with monoclonal antibodies of a surface antigen of Plasmodium falciparum merozoites.
Pirson PJ; Perkins ME
J Immunol; 1985 Mar; 134(3):1946-51. PubMed ID: 3881529
[TBL] [Abstract][Full Text] [Related]
53. A protective merozoite protein of Plasmodium falciparum shares an epitope with surface antigens of Paramecium.
Sehgal A; Singh NJ; Chakraborty T; Sharma S
Parasite Immunol; 2004 May; 26(5):219-27. PubMed ID: 15491471
[TBL] [Abstract][Full Text] [Related]
54. Rodent malaria in the natural host--irradiated sporozoites of Plasmodium berghei induce liver-stage specific immune responses in the natural host Grammomys surdaster and protect immunized Grammomys against P. berghei sporozoite challenge.
Chatterjee S; Ngonseu E; Van Overmeir C; Correwyn A; Druilhe P; Wéry M
Afr J Med Med Sci; 2001; 30 Suppl():25-33. PubMed ID: 14513935
[TBL] [Abstract][Full Text] [Related]
55. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
Bargieri DY; Rosa DS; Braga CJ; Carvalho BO; Costa FT; Espíndola NM; Vaz AJ; Soares IS; Ferreira LC; Rodrigues MM
Vaccine; 2008 Nov; 26(48):6132-42. PubMed ID: 18804504
[TBL] [Abstract][Full Text] [Related]
56. Babesia bigemina: identification of B cell epitopes associated with parasitized erythrocytes.
Vidotto O; McElwain TF; Machado RZ; Perryman LE; Suarez CE; Palmer GH
Exp Parasitol; 1995 Dec; 81(4):491-500. PubMed ID: 8542990
[TBL] [Abstract][Full Text] [Related]
57. [Expression and immunogenicity evaluation of ectodomain and subdomains of Plasmodium berghei apical membrane antigen 1].
Li SL; Zhang DM; Cao Y; Pan WQ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Feb; 25(1):1-5. PubMed ID: 17639690
[TBL] [Abstract][Full Text] [Related]
58. [Plasmodium berghei: antibody response and protective immunity induced by vaccination].
Casaglia O; Zenobi P; Bucci A; Stiffel C; Biozzi G
Parassitologia; 1982 Dec; 24(2-3):121-7. PubMed ID: 6765341
[TBL] [Abstract][Full Text] [Related]
59. Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice.
Sharma SK; Gupta C; Dwivedi V; Misra-Bhattacharya S; Mohammad O
Vaccine; 2007 Mar; 25(11):2103-11. PubMed ID: 17241709
[TBL] [Abstract][Full Text] [Related]
60. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells.
Tarun AS; Dumpit RF; Camargo N; Labaied M; Liu P; Takagi A; Wang R; Kappe SH
J Infect Dis; 2007 Aug; 196(4):608-16. PubMed ID: 17624848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
